What are you looking for?
Start main content



The study of “Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses” is the first to demonstrate a significant detrimental effect on overall survival with continuation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in combination with standard chemotherapy. With EGFR TKIs being the standard first-line therapy, physicians should be warned against their use beyond radiologic disease progression when chemotherapy is initiated (J Clin Oncol. 2017 Oct 2:JCO2017739250. doi: 10.1200/JCO.2017.73.9250. [Epub ahead of print]).
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Tony Mok, Chairman of our Department of Clinical Oncology. Prof Mok’s work focuses on biomarker and molecular targeted therapy in lung cancer and he has lead multiple multi-national studies that helped establish the global standard on personalized medicine for lung cancer.


View the full article: